IMMUNOHISTOCHEMISTRY at Dr. Essa Lab

IMMUNOHISTOCHEMISTRY at Dr. Essa Lab

Immunohistochemistry (IHC) is a highly specialized, state-of-the-art diagnostic technique utilized in histopathology to identify specific proteins (antigens) within tissue samples. By utilizing the precise binding affinity between antibodies and antigens, this laboratory method allows pathologists to visualize the exact distribution and localization of cellular components under a microscope. At Dr. Essa Lab, a premier diagnostic institution in Karachi, Pakistan, immunohistochemistry serves as a cornerstone for advanced oncological diagnostics, infectious disease identification, and therapeutic planning. The test bridges the gap between traditional microscopic morphology and molecular pathology, providing unmatched diagnostic precision.

The fundamental mechanism of immunohistochemistry involves applying chemically labeled antibodies to thin sections of tissue, typically obtained via biopsy or surgical resection. These tissue specimens are preserved as Formalin-Fixed Paraffin-Embedded (FFPE) blocks. When the customized antibody encounters its target antigen within the tissue section, it binds specifically to that site. A secondary detection system, usually involving an enzyme-substrate reaction (such as horseradish peroxidase with diaminobenzidine), produces a visible colored precipitate at the site of antigen-antibody binding. This color change is then evaluated by a consultant pathologist under a high-resolution light microscope to determine the presence, intensity, and cellular localization of the target protein.

The clinical importance of immunohistochemistry cannot be overstated. While routine Hematoxylin and Eosin (H&E) staining provides essential structural and morphological details of a tissue, many tumors appear morphologically identical under a microscope. IHC acts as a molecular map, allowing pathologists to differentiate between look-alike tumors, determine the primary site of metastatic cancers, identify specific subtypes of lymphomas, and detect prognostic markers. This level of detail is critical for modern personalized medicine, ensuring that patients receive targeted therapies tailored to the specific molecular profile of their disease.

Clinical Procedure: What to Expect

Patient Preparation

Because immunohistochemistry is a specialized laboratory analysis performed on tissue samples rather than a direct patient procedure, the preparation depends entirely on how the tissue is acquired:

• Submission of Existing Blocks/Slides: If you are submitting pre-existing formalin-fixed paraffin-embedded (FFPE) tissue blocks or unstained slides prepared by another facility, no physical preparation or fasting is required. You simply need to bring the pathology blocks, slides, and the original histopathology report to Dr. Essa Lab.
• Fresh Biopsy Preparation: If the tissue sample is to be collected via a new biopsy (e.g., core needle biopsy, endoscopic biopsy, or surgical excision), you must follow the specific preparation guidelines provided by your clinical specialist or radiologist.
• Medication Review: Inform your physician of all medications you are currently taking, particularly blood thinners (such as aspirin, warfarin, or clopidogrel), as these may need to be temporarily discontinued before a biopsy.
• Fasting Requirements: Fasting may be required if your biopsy procedure involves local, conscious sedation, or general anesthesia.

During the Procedure

The laboratory phase of immunohistochemistry is a meticulous, multi-step process conducted by skilled histotechnologists and evaluated by consultant pathologists at Dr. Essa Lab:

• Tissue Sectioning: The paraffin-embedded tissue block is mounted on a microtome, and ultra-thin sections (approximately 3 to 5 micrometers thick) are cut and placed onto specialized, positively charged glass slides to prevent tissue detachment.
• Deparaffinization and Rehydration: The slides are heated and treated with solvents like xylene and graded alcohols to remove the paraffin wax and rehydrate the tissue, allowing aqueous antibody solutions to penetrate the cells.
• Antigen Retrieval: The fixation process can mask target proteins. Slides undergo heat-induced epitope retrieval (HIER) or enzymatic epitope retrieval (EIER) using specialized buffers to unmask the target proteins, restoring their ability to bind with antibodies.
• Antibody Incubation: The tissue is incubated with highly specific primary antibodies. After washing away unbound antibodies, a secondary antibody conjugated with an enzyme or fluorophore is applied to amplify the signal.
• Chromogen Visualization: A chromogenic substrate is added, reacting with the enzyme to produce a distinct, colored precipitate (usually brown or red) at the site of the target antigen.
• Counterstaining and Mounting: The slides are counterstained (typically with hematoxylin) to provide contrast for cellular nuclei, dehydrated, and sealed with a coverslip for permanent preservation.
• Pathological Interpretation: A consultant pathologist examines the slides under a microscope, assessing the percentage of positive cells, the intensity of staining, and the sub-cellular localization (nuclear, cytoplasmic, or membranous).

When is a IMMUNOHISTOCHEMISTRY Performed?

1. Classification of Undifferentiated Malignancies

When a patient presents with an advanced tumor that lacks distinct structural features under routine microscopy, it is classified as an undifferentiated or poorly differentiated neoplasm. Symptoms depend on the tumor’s location but often include rapid tissue swelling, unexplained weight loss, and localized pain. Physicians request immunohistochemistry to determine whether the tumor is a carcinoma, sarcoma, lymphoma, or melanoma. By applying a panel of lineage-specific markers (such as Cytokeratins, Vimentin, CD45, and S100), IHC assists the pathologist in establishing an accurate lineage diagnosis, which is critical for selecting the appropriate chemotherapy protocol.

2. Identification of the Primary Site in Metastatic Tumors

Metastatic disease occurs when cancer cells spread from their original site to distant organs, such as the liver, lungs, bones, or brain. Patients may present with symptoms like bone pain, neurological deficits, or shortness of breath without a known primary cancer. In cases of